Cencora, Inc. $COR Shares Purchased by Black Creek Investment Management Inc.

Black Creek Investment Management Inc. boosted its position in Cencora, Inc. (NYSE:COR) by 8.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 46,725 shares of the company’s stock after purchasing an additional 3,734 shares during the quarter. Cencora comprises approximately 0.8% of Black Creek Investment Management Inc.’s investment portfolio, making the stock its 17th biggest holding. Black Creek Investment Management Inc.’s holdings in Cencora were worth $15,781,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Oakworth Capital Inc. acquired a new stake in Cencora in the fourth quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora during the 4th quarter valued at $27,000. Archer Investment Corp lifted its position in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after acquiring an additional 47 shares during the last quarter. IAG Wealth Partners LLC acquired a new stake in shares of Cencora during the 3rd quarter valued at $30,000. Finally, Caitlin John LLC acquired a new stake in shares of Cencora during the 3rd quarter valued at $31,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of NYSE:COR opened at $281.56 on Friday. The company’s fifty day moving average is $289.22 and its two-hundred day moving average is $327.63. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The company has a market cap of $54.78 billion, a P/E ratio of 21.59, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. During the same period last year, the firm earned $4.42 earnings per share. Cencora’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its board has authorized a share buyback program on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s management believes its stock is undervalued.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s dividend payout ratio is 18.40%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Morgan Stanley set a $342.00 price objective on Cencora in a research report on Friday, May 8th. Weiss Ratings downgraded Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 22nd. Barclays cut their price objective on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday. Wells Fargo & Company cut their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Cencora has an average rating of “Moderate Buy” and an average price target of $374.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.